Erasca, Inc. (NasdaqGS: ERAS)
Health Care · Biotechnology · US
$15.71
-2.00% today · +554.3% 1Y
Erasca, Inc. (NasdaqGS: ERAS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.61B and employs 103 people.
Over the last twelve months the share price has gained 554.3%, trading between 2.11 and 24.28.
Tweenvest scores Erasca, Inc. across four factors: quality 49/100, value 82/100. Its strongest factor is value.
ERAS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.61B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.97
- Dividend yield
- —
- Beta (5Y)
- 0.62
- 52-week high
- $24.28
- 52-week low
- $2.11
- Avg volume (3M)
- —
- Shares outstanding
- 349.76M
- Employees
- 103
- Next earnings
- —
About Erasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
- ISIN
- US29479A1088
- Founded
- 2018
- Listed since
- Jul 16, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc.NasdaqGM: RYTM | $6.25B | $90.46 | -0.35% |
| Kiniksa Pharmaceuticals International, plcNasdaqGS: KNSA | $6.22B | $80.38 | +0.75% |
| Biocon LimitedNSEI: BIOCON | $5.88B | Rs349.40 | -5.75% |
| CG Oncology, Inc.NasdaqGS: CGON | $5.66B | $63.82 | 0.00% |
| Mirum Pharmaceuticals, Inc.NasdaqGM: MIRM | $5.58B | $83.13 | -3.35% |
| Oruka Therapeutics, Inc.NasdaqCM: ABIO | $5.44B | $— | — |
| Oruka Therapeutics, Inc.NasdaqGM: ORKA | $5.44B | $80.47 | -2.00% |
| PTC Therapeutics, Inc.NasdaqGS: PTCT | $5.40B | $64.08 | -0.96% |
Figures last refreshed Oct 11, 2026.